Autoimmune Diseases Clinical Trial
Official title:
Incidence and Frequency of Cariogenic Microflora in Patients With Clinical Xerostomia and Autoimmune Disease
This study will examine the types of bacteria present in the dental plaque of patients with
persistent dry mouth. Saliva is essential for digestion and swallowing and for maintaining
the normal mineralization of teeth. People who suffer from dry mouth usually have a
significant increase in tooth decay (caries). This study will determine if this increase is
due solely to reduced salivary flow or also to an increase in certain types of bacteria in
the mouth.
Patients participating in the following NIDCR protocols may be eligible for this study:
Evaluation and Treatment of Salivary Dysfunction (84-D-0056), Natural History of Salivary
Gland Dysfunction and Sjogren's Syndrome Research Project (99-D-0070), and Salivary
Evaluation in Normal Volunteers (94-D-0018).
Participants will have three appointments at the NIH dental clinic as follows:
Visit 1
Dental examination and instruction on keeping a detailed diary of food intake.
Visit 2 (1 week after visit 1)
Attachment of a bacteria collection device (described below) to the side of a tooth.
Visit 3 (48 hours after visit 2)
Removal of the collection device, tooth cleaning and polishing, and submission of food
diary.
The bacteria collection device is a 4mm x 2mm x 2mm square of sterilized tooth obtained from
slicing an extracted healthy tooth donated by another patient. The donated teeth are either
extracted impacted third molars (wisdom teeth) or teeth extracted for teeth straightening
(orthodontics). The device is heat-sterilized before being bonded to the participant's
tooth. The dental cement used for bonding can be removed after 48 hours with no damage to
the surface of the participant's tooth.
Although significant improvements have been made in the dental health status of the US
population, dental caries remains a significant problem. The most recent Surgeon General's
Report (2000) noted that 20% of the US population bears 60% of the caries burden. Caries
incidence is even higher in children of minorities, the chronically ill, the physically
handicapped, the elderly and the institutionalized.
Dental Caries is a multi-factorial disease in which the fermentation of dietary carbohydrate
by oral bacteria results in acid dissolution of tooth structure. Important risk factors
include the frequency of dietary carbohydrate intake, intra-oral plaque levels, the levels
of cariogenic oral bacteria, salivary insufficiency and past fluoride exposure.
A medical condition shown to be associated with increased caries risk and caries incidence
is Sjogren's syndrome (Kolavic et al 1997, Pedersen et al 1999, Almstahl et al 1999).
Sjogren's syndrome (SS) predominantly affects women and is an auto-immune disorder
characterized by an epitheliitis or exocrinopathy. Both primary and secondary forms are
described. Secondary SS sees the condition co-exist with other auto-immune disease such as
rheumatoid arthritis (See reviews by Fox and Maruyama 1997, Fox et al 1999, Pflugfelder 1998
)
A recent study by Sreebny and Zhu (Adv. Dent Res 1996), demonstrated that individuals with a
diagnosis of SS are nearly 40% more likely to harbor high levels of the species
Lactobacillus in plaque and saliva than healthy individuals. LB has been shown in to be a
major etiological agent in dental caries progression.
The principal hypothesis of this study is that SS patients are at a higher risk of caries
development not just because of reduced salivary flow (xerostomia) but also changes in the
output of organic and inorganic microbial regulatory components in saliva secondary to their
auto-immune disease. These alterations favor a selective increase in the proportion of
cariogenic microflora in plaque located on their teeth. Specifically, mutans streptococci
(MS) and Lactobacillus (LB) species are increased in frequency and number in SS patients
compared with xerostomic patients with no detectable auto-immune disease.
The proposed study will investigate microbial counts of MS and LB in the plaque of patients
with a clinical diagnosis of markedly reduced salivary flow (pooled unstimulated flow &eq;
0.1 ml/min). All clinical procedures will take place at NIH. Some samples and all data,
without any patient identifiers, will be analyzed outside.
Plaque samples will be collected from sites identified to be at high-risk for caries
initiation and development. It is generally accepted that discernment of microbial etiology
is blunted by using salivary or pooled plaque monitoring of MS and LB as a surrogate for
samples of plaque in areas of high caries risk. This is supported by current knowledge of
the biology of MS/LB and expected locations of carious lesions.
Saliva samples will not be collected due to difficulties in obtaining sufficient fluid as a
result of the concurrent xerostomia.
The proposed study will examine the relationship between MS/LB and reduced salivary flow in
two patient groups:
1. A patient group with reduced salivary flow AND a diagnosis of primary or secondary SS
(as per the Revised International Criteria for diagnosis of SS) OR auto-immune disease
of non-SS etiology.
2. A non-disease control group, who do not meet the criteria for SS, with reduced salivary
flow AND who have suffered subjective symptoms of xerostomia or xerophthalmia for a
period longer than 6 months OR who are taking medication with xerogenic effect.
Plaque micro-organisms will be harvested from a "collection device" bonded to the surface of
a posterior tooth shown to be at high risk for caries development. Plaque collected in this
way has been shown to closely simulate the complex ecology of a mature cariogenic plaque.
The harvested organisms will then be plated on non-selective media for enumeration of total
microbial load and on selective media for enumeration of specific cariogenic bacteria.
More comprehensive knowledge of the effect of SS on microbial flora in different
predeliction sites for oral diseases would be of great value for effective treatment
planning in SS and for the evaluation of the effect of oral treatments and of preventive
measures implemented in individuals with SS.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04078698 -
Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Completed |
NCT03266172 -
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
|
Phase 1 | |
Completed |
NCT03649412 -
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
|
Phase 1 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Completed |
NCT00975936 -
Phase 0 Microdose Study
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Completed |
NCT01210716 -
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
|
Phase 3 | |
Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Withdrawn |
NCT03239600 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Recruiting |
NCT06019611 -
Epidural Stimulation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05030779 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
|
Early Phase 1 | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04005456 -
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
|
N/A | |
Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
Recruiting |
NCT05853835 -
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
|
Phase 1 |